Core Insights - Infinimmune has entered a partnership with Merck that could be valued at approximately $838 million in milestone payments for the discovery and development of multiple antibodies targeting undisclosed diseases [1][2]. Group 1: Partnership Details - The agreement includes an undisclosed upfront payment to Infinimmune, with potential milestone payments linked to various drug candidates totaling up to $838 million [2]. - Merck will hold exclusive rights to develop and commercialize the antibody candidates resulting from this collaboration [2]. Group 2: Technology and Focus - Infinimmune will utilize its proprietary platform to screen a large number of human immune cells to identify naturally occurring antibodies, employing AI tools for refinement and enhancement [3]. - The specific disease targets selected by Merck for this partnership have not been disclosed [3]. Group 3: Additional Developments - Apart from the collaboration with Merck, Infinimmune is also working on its own early-stage medicines aimed at treating moderate-to-severe eczema and other immune-related diseases [4].

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [29][30] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [32] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [31] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [34] Business Line Data and Key Metrics Changes - The company had 107 active partners by year-end 2025, with 407 active programs, reflecting a net increase of 44 programs during the year [6][12] - The number of program additions in 2025 was 84, significantly higher than in previous years, with over 98% of active programs having contracted future economics to the company [12][13] - The company introduced OmniUltra, a new transgenic chicken platform, which is expected to drive growth and attract new partners [7][26] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [11] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's technology [11] Company Strategy and Development Direction - The company is focused on broadening its partner roster and increasing the number of active programs, with a scalable platform that allows for operational efficiency [9][10] - The introduction of new technologies like OmniUltra and xPloration is expected to enhance growth and expand market reach [7][28] - The company aims to transition from milestone-driven revenue to more royalty-driven revenue, with over $3 billion in contracted milestones [39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong partner engagement and the potential for multiple new entries into clinical development [18][61] - The company anticipates a revenue range of $25 million to $30 million for 2026, indicating a recovery from previous years [37] - The effective tax rate is expected to remain close to 0% due to a full valuation allowance against the income tax benefit associated with net losses [31][38] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments, with expectations to end 2026 with a cash balance of $30 million to $35 million [36][38] - Operating expenses decreased to $87.6 million in 2025 from $100.9 million in 2024, reflecting cost control measures [33] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [42][44] Question: Revenue growth expectations for xPloration - Management indicated significant growth potential for xPloration, with strong demand from high-tier partners and multiple revenue streams expected [45][47] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [50][53] Question: Timeline for achieving cash flow break-even - Management stated that while a precise date for achieving break-even cannot be provided, the growing portfolio gives confidence in reaching that goal [60][61] Question: Initial response to OmniUltra - The launch of OmniUltra has been well-received, with strong engagement and increasing partner programs expected [68][70] Question: Proportion of tiered vs. fixed royalty structures - Management indicated that while most deals are flat royalties, there are some instances of tiered royalties, but it is not the majority [85][89]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [24] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [28] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [26] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [30] Business Line Data and Key Metrics Changes - The company had 107 partners running 407 active programs by year-end 2025, reflecting growth in both partner count and program activity [4][7] - There were 84 program additions in 2025, significantly higher than previous years, with a net increase of 44 programs during the year [9] - Over 98% of active programs have contracted future economics to the company, with total contracted milestone payments exceeding $3 billion [10] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [8] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's partner relationships [8] Company Strategy and Development Direction - The company introduced OmniUltra, a transgenic chicken platform for ultra-long CDRH3s, which is expected to drive growth and attract new partners [5][20] - The xPloration platform, launched in mid-2025, is positioned for significant growth and aims to enhance partner engagement through high-throughput screening capabilities [6][22] - The company is focused on transitioning revenue from milestone-driven to more royalty-driven streams, with an average royalty rate of 3.4% across its portfolio [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing strong partner engagement and the potential for multiple new clinical program entries in 2026 [19][55] - The company anticipates achieving cash flow positivity as it continues to control operating costs while expanding its partner and program portfolio [32] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments, with expectations to end 2026 with a cash balance of $30 million to $35 million [30] - The company implemented workforce reductions of 22 employees in 2025, contributing to lower operating expenses [29] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [34][36] Question: Revenue expectations from xPloration - Management indicated that xPloration is expected to contribute significantly to revenue in 2026, with strong interest from high-tier partners [38][40] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [43][47] Question: Deployment of xPloration systems - Two xPloration instruments were deployed by the end of 2025, with expectations for growth in 2026 [52] Question: Initial response to OmniUltra - The launch of OmniUltra has been well-received, with strong engagement from partners and an increase in partner programs [62][64] Question: Milestones for OmniUltra in 2026 - The focus for 2026 will be on adding partners and programs leveraging OmniUltra technology [74] Question: Royalty structures for active programs - The majority of active programs have flat royalties, with some having tiered structures [78][81]

Core Insights - OmniAb has entered into a technology license and services agreement with Mabtrx Biosciences, a subsidiary of a joint venture between ArrowMark Partners and Viking Global Investors, focusing on antibody discovery programs [1][2][3] Company Overview - OmniAb specializes in licensing advanced discovery research technology to pharmaceutical and biotech companies, enabling the identification of next-generation therapeutics [8] - The company's technology platform utilizes engineered transgenic animals to create optimized antibody candidates, claiming to have the most diverse host systems in the industry [8] Financial Aspects - Under the new agreement, OmniAb will receive revenue for services, potential equity, and royalties from the discovery of novel antibodies for targets defined by Mabtrx [2][3] Strategic Partnerships - The collaboration with ArrowMark and Viking is seen as a strategic move to leverage OmniAb's unique technologies for value creation in drug discovery [3] - ArrowMark Partners is known for its focus on niche market segments and has a history of successful biotech investments [4] - Viking Global Investors manages over $55 billion in capital and employs a long-term, research-intensive investment approach [5]

Summary of AbCellera Biologics (ABCL) FY Conference Call - June 09, 2025 Company Overview - **Company**: AbCellera Biologics (ABCL) - **Transition**: Shifted from a platform company to a clinical-stage biotech with two internally developed agents authorized for clinical trials [3][4] Key Points and Arguments Financial Position - **Liquidity**: Company has approximately $800 million in liquidity, allowing for continued investment in pipeline development [3] Pipeline Development - **Initial Molecules**: Focus on two molecules, ABCL635 and ABCL575, entering clinical trials in Q3 2025 [3] - **Development Projects**: Over 20 development projects, with more than half targeting complex membrane protein targets [4] Target Selection Framework - **Framework Criteria**: Selection based on validated science, large commercial opportunities, differentiation, and clear development paths [5][6] ABCL635 Specifics - **Indication**: Targeting vasomotor symptoms (VMS) related to menopause, specifically hot flashes [8] - **Market Opportunity**: Estimated annual sales potential over $2 billion, with 30% of women experiencing moderate to severe VMS [10] - **Differentiation**: Antibody approach expected to have fewer safety issues compared to small molecules, with a preference for monthly dosing over daily oral administration [20][21] Market Dynamics - **Menopausal Hormone Therapy (MHT)**: Approximately 40 million women in the U.S. are of menopausal age, with 30% experiencing moderate to severe VMS. About 50% seek treatment, but 20% are contraindicated for MHT [25][26][27] - **Commercial Market**: Significant opportunity exists for alternatives to MHT, especially for the 1.2 million women contraindicated for MHT [28] ABCL575 Overview - **Mechanism**: Targets OX40 ligand, which mediates T cell expansion and survival, potentially offering safety advantages over OX40 receptor targeting [35] - **Indication**: Initially exploring atopic dermatitis, a large unmet medical need with existing successful treatments like Dupixent [38] Competitive Landscape - **Dupixent Comparison**: Dupixent generates $8 billion in sales but has limitations in patient response rates, indicating a potential market for alternative therapies like ABCL575 [41] Clinical Trials and Future Plans - **Phase One Trials**: Expected to start dosing in Q3 2025, with initial data anticipated in the first half of 2026 [49][50] - **Partnership Strategy**: ABCL635 is likely to be advanced independently, while ABCL575 may be better suited for partnership due to its broader indication potential [54][60] Legacy Business and Partnerships - **Ongoing Partnerships**: Continued investment in partnerships, including a recent collaboration with AbbVie on T cell engagers [61] - **GMP Facility**: Investment in a GMP facility expected to be operational by the end of the year, supporting clinical trial material production [62] Additional Important Content - **Patient Preferences**: Surveys indicate a preference for injectable treatments over daily oral medications among menopausal women [21][23] - **Market Segmentation**: There is room for both biologics and oral treatments in the market, with patient choice being a significant factor [32] This summary encapsulates the key insights from the conference call, highlighting the strategic direction, market opportunities, and clinical development plans of AbCellera Biologics.

TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Table of Contents As filed with the Securities and Exchange Commission on February 6, 2023 Registration No. 333-268613 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 OMNIAB, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 8731 98-1584818 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identif ...